SpainTuberculosis profile
Population  2015 46 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.26 (0.26–0.27) 0.57 (0.57–0.58)
Mortality (HIV+TB only) 0.054 (<0.01–0.27) 0.12 (0–0.58)
Incidence  (includes HIV+TB) 5.5 (4.7–6.4) 12 (10–14)
Incidence (HIV+TB only) 0.4 (0.34–0.48) 0.87 (0.73–1)
Incidence (MDR/RR-TB)** 0.042 (0.016–0.069) 0.09 (0.03–0.15)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.18 (0.092–0.26) 2 (1.5–2.6) 2.2 (1.5–2.9)
Males 0.21 (0.14–0.28) 3.1 (2.4–3.8) 3.3 (2.6–4.1)
Total 0.39 (0.29–0.49) 5.1 (4.7–5.6) 5.5 (4.7–6.4)
TB case notifications, 2015  
Total cases notified 4 191
Total new and relapse 4 026
          - % tested with rapid diagnostics at time of diagnosis 11%
          - % with known HIV status  
          - % pulmonary 74%
          - % bacteriologically confirmed among pulmonary 82%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 73% (63–85)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.06 (0.03–0.09)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  25
(10–40)
Estimated % of TB cases with MDR/RR-TB 0.44% (0.12–1.1) 7.1% (3.3–13)  
% notified tested for rifampicin resistance      
MDR/RR-TB cases tested for resistance to second-line drugs    
Laboratory-confirmed cases MDR/RR-TB: , XDR-TB:
Patients started on treatment **** MDR/RR-TB: , XDR-TB:
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 58% 4 689
Previously treated cases, excluding relapse, registered in 2014 52% 228
HIV-positive TB cases, all types, registered in 2014 39% 200
MDR/RR-TB cases started on second-line treatment in 2013    
XDR-TB cases started on second-line treatment in 2013    
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data